NFL Biosciences: success of smoking cessation study

(CercleFinance.com) - NFL Biosciences shares soared on the Paris Bourse on Tuesday, following the biopharmaceutical company's announcement of the success of a study conducted in smoking cessation with the French Atomic Energy Commission (CEA).


The French company, which develops botanical medicines for the treatment of dependencies and addictions, reports that the model set up with the CEA (Commissariat à l'énergie atomique et aux énergies alternatives) enabled it to demonstrate the mechanism of action of its candidate.

In detail, the study demonstrated the ability of NFL-101 to reduce craving by restoring normal brain activity in the region associated with craving.

These results also suggest communication between the immune system and the central nervous system, a different mode of action from current smoking cessation drugs which directly target nicotinic receptors.

The study was conducted by CEA's pharmacological neuroimaging team at the Service Hospitalier Frédéric Joliot (SHFJ) in Orsay, France, using tomographic imaging to monitor brain function associated with the development of tobacco dependence in mice.

NFL-101 is a nicotine-free tobacco extract derived from a subcutaneous desensitization treatment initially developed by the Pasteur Institute to treat tobacco allergies in tobacco factory workers.

At around 11:00 a.m., the share price was up 63%, by far the biggest gainer on the Paris market, with volumes already 25 times the average for the last four trading sessions.

Copyright (c) 2024 CercleFinance.com. All rights reserved.